April 17, 2025 7:45am

With an econ rope around the neck of portfolio having been “conflicted” in previous sessions of no confidence and expectation

Pre-open Indications: 5 Positive

News:  uniQure N.V. (QURE +$3.1 or +33%) the FDA has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington’s disease, a rare, inherited neurodegenerative disorder for which there are currently no disease-modifying therapies available. This designation is in addition to Regenerative Medicine Advanced Therapy (RMAT) designation, Orphan Drug designation and Fast Track designation, all previously granted by the FDA to AMT-130.

Breaking News: Jobless claims for the week that ended April 12 totaled 215,000, while economists expected a print of 225,000. The report comes as investors assess the effect of tariffs on the U.S. economy.

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: never assume nothin’ … https://www.regmedinvestors.com/articles/13883

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812

 

Thursday: The pre-open Dow futures are DOWN -1.49% or (-595 points), the S&P futures are UP +0.39% or (+20.75 points) and the Nasdaq futures are UP +0.64% or (+118 points)

  • Futures are mixed; Thursday, 4/17
  • European markets were lower,
  • Asia-Pacific markets rose

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Wednesday: The Dow closed DOWN -699.57 points or -1.73%, the S&P closed DOWN -120.93 points or -2.24% while the Nasdaq close DOWN -516.01 points or -3.07%

  • Tuesday: The Dow closed DOWN -155.83 points or -0.38%, the S&P closed DOWN -9.34 points or -0.17% while the Nasdaq close DOWN -8,32 points or -0.05%
  • Monday: The Dow closed UP +312.08 points or +0.78%, the S&P closed UP +42.61 points or +0.79% while the Nasdaq close UP +107.03 points or +0.64%

Economic Data Docket: Initial jobless claims, Housing starts – March, Building permits and March and Philadelphia Fed manufacturing survey

               

Q2- April – 7 negative and 5 positive closes

  • Q1/25 – March, 10 positive and 11 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Although … trending tickers … MY thoughts

Positive Indications:

Mesoblast (MESO) closed down -$0.46 with a positive +$0.33 or +3.20%

Alnylam Pharmaceuticals (ALNY) closed down -$0.43 after Tuesday’s -$9.08, Monday’s +$2.24 and last Friday’s +$11.49 with a positive +$0.65 or +0.28% pre-market.

Blueprint Medicine (BPMC) closed up +0.66 after Tuesday’s -$1.08 and Monday’s +$1.69 with a positive +$0.89 or +1.08% pre-open

Ultragenyx Pharmaceuticals (RARE closed down -$0.36 after Tuesday’s +$0.42, Monday’s +$0.78, last Friday’s +$0.98, and the previous Thursday’s -$0.75, with a positive +$0.71 or +2.03% pre-open

uniQure NV (QURE) closed down -$0.26 with a positive +3.11 or +33% pre-open on news

 

The BOTTOM LINE:  I am STILL in a RISK-ON mood! There is still a fog of uncertainty.

The cell and gene therapy sector companies are showing signs of being … “alternated” !

 

April ‘25: understand the “flow” of bad market and economic karma…

  • 4/16 – Wednesday closed negative with 2 positive, 31 negative and 2 flats
  • 4/14 – Tuesday closed barely positive with 17positive, 16 negative and 2 flats
  • 4/13 – Monday closed positive with 23 positive, 7 negative and 5 flats
  • 4/11 - Friday closed positive with 28 positive, 5 negative and 2 flats
  • 4/10 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 4/9 – Wednesday closed positive with 33 positive, 1 negative and 1 flat
  • 4/8 - Tuesday closed negative with 4 positive, 30 negative and 1 flat
  • 4/7 - Monday closed negative with 13 positive, 20 negative and 2 flats
  • 4/4 – Friday closed negative with 3 positive, 30 negative and 2 flats
  • 4/3 – Thursday closed negative with 2 positive, 32 negative and 1 flat
  • 4/2 - Wednesday closed positive with 9 positive, 25 negative and 1 flat
  • 4/1 - Tuesday closed negative with 5 positive, 28 negative and 2 flats

 

Brace ourself for more economics and their down trending affect?

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.